ArmaGen Technologies is both a platform technology company and a products company. The platform technology produces IgG fusion proteins formed by fusion of a recombinant protein therapeutic, which does not cross the BBB to an IgG. The IgG domain of the fusion protein is a genetically engineered monoclonal antibody, which crosses the human BBB via transport on endogenous BBB receptors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/30/12 | $17,000,000 | Series A |
Boehringer Ingelheim Venture Fund Mitsui Global Investment Shire Strategic Investment Group Takeda Ventures | undisclosed |
